Rating: HOLD
| Metric | Value |
|---|---|
| Current Price | $103 |
| Triangulated Fair Value | $81 |
| 12-mo Scenario PWEV | $103 |
| Implied Return | -22% |
| Forward P/E | 14.0x |
| Market Cap | $132B |
| 52-Week Range | $57 – $105 |
Methodology: Valuation triangulated across five independent anchors — Monte Carlo (Student-t + regime switching), an independent DCF, peer re-rating, a sum-of-parts, and a scenario-weighted PWEV. Figures reconciled to Alpha Vantage 2026-06-27. Each chart below sits with the part of the thesis it evidences.
Investment Thesis
The bull case — 'Bull — Margin Recovery / Re-Rate' (8% weight) — targets $183, +76% vs spot. It needs Gross Margin to surprise to the upside.
The dashboard below is the whole argument on one page: spot ($103) against each valuation anchor, the scenario tree, technicals and the options-implied move.
Anti-Thesis (The Real Bear Case)
The structural case — 'Structural — Medicare/Medicaid Reform / MLR Squeeze' (20%) — targets $45, -56% vs spot. This sits below the 52-week low — a genuine structural impairment, not a mild pullback.
Key Debate
Gross Margin explains 68% of Monte Carlo outcome variance — the single variable that decides which side is right.
Earnings-Call Disconfirmation & Sentiment
Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.
Management vs analyst tone (2026Q1): management +0.41 vs analyst floor +0.00 → delta +0.41 (n=27 mgmt / 8 Q&A; 55th pctile across the S&P book, z +0.1).
Flag: TYPICAL — management-vs-analyst tone within the normal cross-sectional range.
| Quarter | Mgmt | Analyst | Delta |
|---|---|---|---|
| 2026Q1 | +0.41 | +0.00 | +0.41 |
| 2025Q4 | +0.37 | +0.00 | +0.37 |
| 2025Q3 | +0.47 | +0.20 | +0.27 |
| 2025Q2 | +0.42 | +0.35 | +0.07 |
News (last 365d, 1000 articles): avg ticker sentiment +0.19 (bullish 26% / bearish 3%)
Scenario Analysis
The tree runs from a structural 'Structural — Medicare/Medicaid Reform / MLR Squeeze' downside ($45) to a 'Bull — Margin Recovery / Re-Rate' bull case ($183); the probability-weighted blend (PWEV $103) is -0% versus spot.
| Scenario | Probability | Target | Return |
|---|---|---|---|
| Structural — Medicare/Medicaid Reform / MLR Squeeze | 20% | $45 | -56% |
| Cost-Trend Spike / Rate Inadequacy | 17% | $77 | -25% |
| Base — Membership + Premium Growth | 35% | $107 | +4% |
| Growth — MA / Care-Services (Optum-style) | 20% | $145 | +40% |
| Bull — Margin Recovery / Re-Rate | 8% | $183 | +76% |
| Probability-Weighted (PWEV) | — | $103 | -0% |
Scenario rationale — what each probability buys (the driver path behind every target):
- Structural — Medicare/Medicaid Reform / MLR Squeeze (20%, $45). Structural impairment — Medicare/Medicaid reform / MLR squeeze: earnings AND the multiple compress together. Target sits below the 52-week low by construction. Drivers — implied_target: 45.4; probability: 0.2.
- Cost-Trend Spike / Rate Inadequacy (17%, $77). Cyclical downturn — membership + premium growth vs medical-cost trend (MLR) + Medicare/Medicaid policy weakens for 1–2 years before normalising. Drivers — implied_target: 77.1; probability: 0.17.
- Base — Membership + Premium Growth (35%, $107). Mid-cycle — normalised membership + premium growth vs medical-cost trend (MLR) + Medicare/Medicaid policy; disciplined capital allocation; steady returns. Drivers — implied_target: 107.08; probability: 0.35.
- Growth — MA / Care-Services (Optum-style) (20%, $145). Upside — MA + care-services growth lifts earnings above mid-cycle; the multiple expands modestly. Drivers — implied_target: 144.56; probability: 0.2.
- Bull — Margin Recovery / Re-Rate (8%, $183). Upside tail — sustained tight conditions or a structural re-rate on MA + care-services growth. Drivers — implied_target: 182.57; probability: 0.08.
Valuation Triangulation
Five anchors — but read them with their basis in mind. The Monte Carlo, the DCF terminal, and the peer re-rate all key off a market multiple, so they are not fully independent; only the discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat five numbers as five independent votes.
| Method | Basis | Fair Value | vs Spot |
|---|---|---|---|
| Monte Carlo median (Student-t + regime) | multiple | $91 | -12% |
| Peer P/E re-rate | multiple | $109 | +5% |
| Peer EV/Revenue re-rate | multiple | $562 | +444% |
| Scenario PWEV | multiple | $103 | -0% |
| DCF (5-year + terminal) | cash flow + terminal × | $52 | -50% |
| Triangulated (weighted) | — | $81 | -22% |
Rating vs blend — the key debate. The rating tracks the multiple-discipline fair value (Monte Carlo $91 + scenario PWEV $103, ≈ spot); the weighted blend $81 (-22%) sits below it because the cash-flow DCF ($52) is materially more conservative than the market multiple. Whether the current multiple is justified is the central question for this name — and the principal downside risk to the rating.
Monte Carlo — the distribution, not a point
10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $91 and 41% of paths finish above spot. The variance decomposition shows the gross margin is the dominant swing factor (68% of variance). The fundamental driver, not the multiple, sets the spread — a cleaner setup.
DCF — the cash-flow anchor
Independent of the market multiple: a 5-year path, WACC 8.5%, 12x terminal FCF multiple → $52. This anchor is deliberately the heaviest (41%): it is the valuation least hostage to the current multiple regime.
Peer benchmarking — relative value
Against the peer cohort, re-rating to the peer-median forward multiple (P/E 14.75x) implies $109. A premium is only justified by superior growth/margins; otherwise it is multiple risk. Weighted just 12% so the market's mood does not drive the fair value.
Across all anchors the spread is wide (genuine disagreement — low valuation confidence).
Revenue-Segment Breakdown
The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)
| Segment | Revenue | Mix | Growth | Op margin | Multiple | Capex % | Tag |
|---|---|---|---|---|---|---|---|
| Managed Care / Health Services | $405.6B | 100% | 8% | 3% | 14x | 2% | ESTIMATE |
Named Exposures
Demand & pricing cycle (FACT/ESTIMATE)
| Dimension | Assessment |
|---|---|
| driver | membership + premium growth vs medical-cost trend (MLR) + Medicare/Medicaid policy |
| net_debt_or_cash_b | -68.8 |
Capital intensity & shareholder returns (ESTIMATE)
| Dimension | Assessment |
|---|---|
| capex_pct_revenue | 0.02 |
| div_yield | 0.0261 |
Structural risk vs optionality (INFERENCE)
| Dimension | Assessment |
|---|---|
| downside | Medicare/Medicaid reform / MLR squeeze |
| upside | MA + care-services growth |
Industry Context — Health Payers Providers
This name sits in the Health Payers Providers as a managed_care. membership + premium growth vs medical-cost trend (MLR) + Medicare/Medicaid policy Its scenarios are not guessed in isolation — they inherit a single, shared view of the cluster's driver cycle, so the names that depend on the same event are mutually consistent.
Value chain: UNH (managed_care) · CVS (managed_care) · HCA (providers) · ELV (managed_care) · CI (managed_care) · HUM (managed_care) · CNC (managed_care) · DVA (providers) · UHS (providers)
| Shared state | Capex path | House view | This name implies |
|---|---|---|---|
| Cost-Trend Spike / Reimbursement-Reform Squeeze | 37% | 37% | |
| Mid-Cycle — Membership & Volume Growth | 35% | 35% | |
| Upside — Margin Recovery / Care-Services | 28% | 28% |
On the cluster's key downside — Cost-Trend Spike / Reimbursement-Reform Squeeze () — this name implies 37% vs the cluster house view of 37% (in line with the house). The cluster's full cross-stock reconciliation governs that the names which ride the same capex cycle assign it comparable odds.
Structure: Shared State — The health_payers_providers cycle is the shared macro driver. Driver — medical-cost trend (MLR) + utilization + reimbursement/regulation Dispersion — Members differ by cyclicality (quality compounders vs deep cyclicals).
Model Appendix
DCF — line items
| Year | Revenue | Op income | − Capex | + D&A | FCF | PV(FCF) |
|---|---|---|---|---|---|---|
| FY+1 | $438B | $13B | $9B | $9B | $10B | $9B |
| FY+2 | $469B | $14B | $9B | $9B | $10B | $9B |
| FY+3 | $497B | $15B | $10B | $9B | $11B | $8B |
| FY+4 | $522B | $16B | $10B | $9B | $11B | $8B |
| FY+5 | $548B | $17B | $11B | $10B | $12B | $8B |
| Terminal | — | — | — | — | $12B × 12x | $93B |
FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 2% of revenue, weighted from the segments) — not a single conversion fudge.
WACC 8.5% · Σ PV(FCF) $42B + PV(terminal) $93B = EV $135B; + net cash → equity $66B ÷ diluted shares 1.28B = $52/share (exit-multiple terminal).
- Gordon (perpetuity-growth) terminal at 2.5% → $83/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
- Incremental ROIC on the forecast capex ≈ 6% vs WACC 8% → below WACC — the incremental build is value-dilutive.
Peer set
| Peer | EV/Rev | Fwd P/E | Growth | Op margin |
|---|---|---|---|---|
| CI | 0.353x | 9.29x | 8% | 6% |
| DGX | 2.558x | 19.19x | 3% | 14% |
| LH | 1.98x | 14.79x | 3% | 11% |
| DVA | 1.897x | 14.71x | 4% | 14% |
| Median | 1.9385x | 14.75x | — | — |
Peer-median fwd P/E → $109; EV/Rev → $562.
Weighted fair-value math
| Anchor | Value | Weight | Contribution |
|---|---|---|---|
| DCF | $52 | 41% | $21 |
| Scenario PWEV | $103 | 29% | $30 |
| Monte Carlo median | $91 | 18% | $16 |
| Peer P/E | $109 | 12% | $13 |
| Triangulated | — | 100% | $81 |
Sensitivity
DCF/share — WACC × terminal multiple
| WACC ＼ Term× | 8.4x | 10.2x | 12.0x | 13.8x | 15.6x |
|---|---|---|---|---|---|
| 6% | $37 | $49 | $61 | $73 | $85 |
| 8% | $33 | $45 | $56 | $68 | $79 |
| 8% | $30 | $41 | $52 | $63 | $74 |
| 10% | $27 | $37 | $48 | $58 | $69 |
| 10% | $24 | $34 | $44 | $54 | $64 |
DCF/share — revenue CAGR Δ × op-margin Δ
| CAGRΔ ＼ MgnΔ | -3.0pp | -1.5pp | +0.0pp | +1.5pp | +3.0pp |
|---|---|---|---|---|---|
| -3.0pp | $-55 | $-6 | $44 | $94 | $144 |
| -1.5pp | $-58 | $-5 | $48 | $101 | $154 |
| +0.0pp | $-61 | $-4 | $52 | $108 | $165 |
| +1.5pp | $-64 | $-4 | $56 | $116 | $176 |
| +3.0pp | $-67 | $-3 | $61 | $124 | $188 |
Tornado — DCF/share swing by driver (widest first)
| Driver | Low | High | Swing |
|---|---|---|---|
| Op margin ±3pp | $-61 | $165 | $225 |
| Terminal × ±15% | $41 | $63 | $22 |
| Revenue CAGR ±3pp | $44 | $61 | $16 |
| WACC ±1pp | $48 | $56 | $8 |
| FCF conversion ±10% | $52 | $52 | $0 |
Company lever — SoP/share vs Managed Care / Health Services multiple (AI re-rating) (base 14x)
| Multiple | 9.8x | 11.9x | 14.0x | 16.1x | 18.2x |
|---|---|---|---|---|---|
| SoP/share | $3,061 | $3,729 | $4,396 | $5,064 | $5,731 |
Load-Bearing Assumptions
DCF: WACC 8%, terminal multiple 12×, FY+5 revenue $548B. Triangulation leans 41% on DCF, 29% on PWEV.
Reasons the Thesis Could Fail (Falsifiable)
A miss on Gross Margin drops the case toward the structural target $45.
Fact / Inference / Speculation
- FACT: Spot $103; 52-week range $57–$105; engine rating HOLD; base-case target $103 (-0%).
- INFERENCE: Triangulated FV $81 (-22%). Gross Margin explains 68% of Monte Carlo outcome variance — the single variable that decides which side is right.
- SPECULATION: At current prices the embedded bet is that Gross Margin surprises to the upside — Gross Margin carries 68% of outcome variance.
Recommendation: HOLD
Balanced: triangulated fair value $81 (-22% vs spot); the outcome hinges on Gross Margin. The debate is Gross Margin (68% of variance) — a fundamental call. SBC runs —M TTM (disclosed in the appendix).